Acumen Pharmaceuticals (ABOS) grants CFO new RSUs and stock options

Rhea-AI Filing Summary

Acumen Pharmaceuticals reported that its CFO and Chief Business Officer, Matt Zuga, received new equity awards. On 01/16/2026, he was granted 99,133 shares of Common Stock as a restricted stock unit (RSU) award at a price of $0 per share, increasing his directly held Common Stock to 309,084 shares.

On the same date, he also received an Employee Stock Option to buy 148,700 shares of Common Stock at an exercise price of $1.89 per share, with 148,700 derivative securities held directly after the grant. The RSUs vest in three equal annual installments starting one year after the grant date, while the stock options vest in 48 equal monthly installments and become fully vested on the fourth anniversary of the grant date, in each case contingent on his continuous service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Zuga Matt

Role CFO & Chief Business Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	148,700	$0.00	--
Grant/Award	Common Stock	99,133	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 148,700 shares (Direct); Common Stock — 309,084 shares (Direct)

Footnotes (1)

1. Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date. The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zuga Matt

(Last) (First) (Middle)

C/O ACUMEN PHARMACEUTICALS, INC.

1210-1220 WASHINGTON STREET, SUITE 210

(Street)

NEWTON MA 02465

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Acumen Pharmaceuticals, Inc. [ ABOS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO & Chief Business Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/16/2026		A		99,133(1)	A	$0	309,084	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$1.89	01/16/2026		A		148,700		(2)	01/16/2036	Common Stock	148,700	$0	148,700	D

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date.

2. The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date.

Remarks:

	/s/ Derek Meisner, Attorney-in-Fact	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Acumen Pharmaceuticals (ABOS) disclose?

The company disclosed that CFO and Chief Business Officer Matt Zuga received 99,133 restricted stock units and an option to buy 148,700 shares of Common Stock on 01/16/2026.

How many Acumen Pharmaceuticals (ABOS) shares does the CFO hold after this Form 4?

After the reported RSU grant, Matt Zuga beneficially owns 309,084 shares of Acumen Pharmaceuticals Common Stock directly.

What are the terms of the RSU grant reported by Acumen Pharmaceuticals (ABOS)?

The 99,133 RSUs each represent a right to receive one share of Common Stock and will vest in three equal annual installments starting one year after the grant date, subject to continuous service.

What are the terms of the stock options granted to the Acumen (ABOS) CFO?

The Employee Stock Option covers 148,700 shares of Common Stock at an exercise price of $1.89 per share and vests in 48 equal monthly installments, becoming fully vested on the fourth anniversary of the grant date, subject to continuous service.

Are the Acumen Pharmaceuticals (ABOS) insider awards direct or indirect holdings?

Both the RSUs and the stock options are reported as directly held by the CFO, with no nature of indirect beneficial ownership indicated.

Does the Acumen Pharmaceuticals (ABOS) Form 4 indicate a sale of shares?

No, the Form 4 reports awards of RSUs and stock options coded as acquisitions, with no dispositions of shares reported.